MetaCap

Gossamer Bio Inc. (GOSS)

NASDAQ: GOSSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

10.72-0.51 (-4.54%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GOSS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$65.57M
EPS (TTM)
-$42.41
52-week range
8.29 – 309.60
Day range
10.65 – 11.60
Volume / Avg
191.36K / 243.40K
Beta
—

52-week range

$8.29$309.60

GOSS stock today

Shares of Gossamer Bio (GOSS) finished lower on Nov 20 at $10.72, a drop of 4.54% or $0.51 per share, versus the S&P 500's 3.70% decline. At this level, GOSS sits near the bottom of its 52-week range of $8.29 to $309.60: 96.5% below the high, set on Dec 15, 2025 and 29.3% above the low. GOSS is down 95.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 95.6%.

Gossamer Bio has posted a net loss over the last twelve months (EPS of -$42.41), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Gossamer Bio

Company profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Faheem Hasnain
Headquarters
San Diego, CA
Employees
161
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Gossamer Bio generated $48.5 million in revenue, down 57.7% from fiscal 2024, the first decline in the 9 years shown. Gossamer Bio reported a net loss of $170.4 million, compared with a loss of $56.5 million a year earlier. Operating margin was -352.2%.

Gossamer Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$48.47M$114.70M$0$0—
Growth-57.74%————
Net income$-170.37M$-56.53M$-179.82M$-229.38M$-234.00M
EPS (diluted)$-0.75$-0.25$-1.18$-2.71$-3.13

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$82.48+669.40%

  • Strong buy 1
  • Buy 2
  • Hold 3
  • Sell 0
  • Strong sell 1

Target range

Low $22.40High $120.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-1.19 vs $-5.55
Surprise
+78.56%

GOSS news

All GOSS news

Gossamer Bio peers

Health Care sector
GOSS peer companies
CompanyPrice% ChgMarket capCompare
PMVPPMV Pharmaceuticals Inc.0.876-33.13%$66.17Mvs GOSS
PLYXPolaryx Therapeutics Inc.1.33-11.92%$66.30Mvs GOSS
FBIOFortress Biotech Inc.1.90+7.34%$64.11Mvs GOSS
MNOVMedicinova Inc1.31+3.15%$67.11Mvs GOSS
CINGCingulate Inc.4.51-14.26%$67.48Mvs GOSS
MAIAMAIA Biotechnology Inc.1.11-2.63%$68.54Mvs GOSS
VTVTvTv Therapeutics Inc. Class A15.51-5.20%$62.22Mvs GOSS
COYACoya Therapeutics Inc.2.95-1.01%$69.20Mvs GOSS

Indexes, lists and sector

Gossamer Bio stock FAQ

What is Gossamer Bio's stock price today?

GOSS last traded at $10.72 as of Nov 20, 4:00 PM EST, down 4.54% on the day. Prices are delayed at least 15 minutes.

Does Gossamer Bio pay a dividend?

No. Gossamer Bio does not currently pay a regular cash dividend.

Who is Gossamer Bio's CEO?

Mr. Faheem Hasnain is the chief executive officer of Gossamer Bio Inc., which has about 161 employees.

Has GOSS ever split its stock?

Yes. The most recent GOSS stock split was a 1-for-80 split on Sep 11, 2026.

What is the GOSS 52-week high?

The 52-week high for GOSS is $309.60 and the 52-week low is $8.29. The stock is currently 96.5% below its high.

Compare GOSS